Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Gastric
Descriptor: Met expression


Reference Number: 41
Wu, C. W. et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5, 817-22. (1998).
PubMed link      E-mail link

Reference Number: 42
Amemiya, H. et al. c-Met expression in gastric cancer with liver metastasis. Oncology 63, 286-96 (2002).
PubMed link      E-mail link

Reference Number: 43
Nakajima, M. et al. The prognostic significance of amplification and overexpression of c- met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894-902. (1999).
PubMed link      E-mail link

Reference Number: 44
Taniguchi, K. et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82, 2112-22 (1998).
PubMed link      E-mail link

Reference Number: 243
Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 161:249-55 (2003).
PubMed link      E-mail link

Reference Number: 315
Wang JY, Hsieh JS, Chen CC, Tzou WS, Cheng TL, Chen FM, Huang TJ, Huang YS, Huang SY, Yang T, Lin SR. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J Surg Res 120, 242-8 (2004)
PubMed link      E-mail link

Reference Number: 317
Amemiya H, Kono K, Takahashi A, Kamei S, Sugai H, Ichihara F, Fujii H, Matsumoto Y. c-Met expression in a gastric cancer cell line producing alpha-fetoprotein. Surg Today 34, 115-22 (2004)
PubMed link      E-mail link

Reference Number: 318
Tang Z, Zhao M, Ji J, Yang G, Hu F, He J, Shen H, Gao Z, Zhao A, Li J, Lu Y. Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 11, 333-9 (2004)
PubMed link      E-mail link

Reference Number: 327
Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N, Miyazawa K. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95, 803-8 (2004)
PubMed link      E-mail link

Reference Number: 361
Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol. 93, 30-5 (2006)
PubMed link      E-mail link

Reference Number: 396
Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Hölscher AH, Mönig SP. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 19, 1477-83 (2008)
PubMed link      E-mail link

Reference Number: 488
Luo B, Wang Y, Wang XF, Gao Y, Huang BH, Zhao P. Correlation of Epstein-Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinoma. World J Gastroenterol. 12, 1842-8 (2006)
PubMed link      E-mail link

Reference Number: 891
Chen JH, Wu CW, Kao HL, Chang HM, Li AF, Liu TY, Chi CW. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Lett. 239, 263-70 (2006)
PubMed link      E-mail link

Reference Number: 897
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer. Korean J Intern Med. 21, 20-7 (2006)
PubMed link      E-mail link

Reference Number: 948
Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res. 16, 3933-43 (2010)
PubMed link      E-mail link

Reference Number: 949
Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70, 7580-90 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 974
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25, 1517-24 (2011)
PubMed link      E-mail link

Reference Number: 1072
Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K. Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer. 105, 407-12 (2011)
PubMed link      E-mail link

Reference Number: 1073
Kitamura S, Miyazaki Y, Hiraoka S, Toyota M, Nagasawa Y, Kondo S, Kiyohara T, Shinomura Y, Matsuzawa Y. PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochem Biophys Res Commun. 265, 453-6 (1999)
PubMed link      E-mail link

Reference Number: 1119
Zhao J, Zhang X, Xin Y. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol. 26, 1111-20 (2011)
PubMed link      E-mail link

Reference Number: 1124
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 20, 1021-7 (2011)
PubMed link      E-mail link

Reference Number: 1145
Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 130, 2912-21 (2012)
PubMed link      E-mail link

Reference Number: 1203
Wang XL, Chen XM, Fang JP, Yang CQ. Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo. Acta Pharmacol Sin. 33, 513-22 (2012)
PubMed link      E-mail link

Reference Number: 1205
Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 11, 660-9 (2012)
PubMed link      E-mail link

Reference Number: 1218
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 106, 304-10 (2012)
PubMed link      E-mail link

Reference Number: 1225
Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol. 7, 57 (2012)
PubMed link      E-mail link

Reference Number: 1226
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 107, 325-33 (2012)
PubMed link      E-mail link

Reference Number: 1261
Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer Lett. 332, 74-82 (2013)
PubMed link      E-mail link

Reference Number: 1334
Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 119, 1627-35 (2013)
PubMed link      E-mail link

Reference Number: 1406
Yashiro M1, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer 109, 2619-28 (2013)
PubMed link      E-mail link

Reference Number: 1407
Gomes C1, Osório H, Pinto MT, Campos D, Oliveira MJ, Reis CA. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One. 8, e66737 (2013)
PubMed link      E-mail link

Reference Number: 1422
Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer. 110, 1169-78 (2014)
PubMed link      E-mail link

Reference Number: 1453
Yamaguchi H1, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. Cancer Sci. 105, 528-36 (2014)
PubMed link      E-mail link

Reference Number: 1498
Kang BW, Lee D, Chung HY, Han JH, Kim YB. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. J Cancer Res Clin Oncol. 139, 1835-43 (2013)
PubMed link      E-mail link

Reference Number: 1528
Ma J, Ma J, Meng Q, Zhao ZS, Xu WJ. Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma. Pathol Oncol Res. 19, 821-32 (2013)
PubMed link      E-mail link

Reference Number: 1563
Wu JG, Yu JW, Wu HB, Zheng LH, Ni XC, Li XQ, Du GY, Jiang BJ. Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma. BMC Res Notes. 7, 6 (2014)
PubMed link      E-mail link

Reference Number: 1566
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Ignatius Ou SH, Kim KM. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 26, 1632-41 (2013)
PubMed link      E-mail link

Reference Number: 1584
Ha SY, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer. Ann Surg Oncol. 21, 1099-106 (2014)
PubMed link      E-mail link

Reference Number: 1595
Peng Y, Guo JJ, Liu YM, Wu XL MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 34 (3) (2014)
PubMed link      E-mail link

Reference Number: 1617
Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. Cancer Biol Ther. 15, 721-34 (2014)
PubMed link      E-mail link

Reference Number: 1626
Liu H, Qian C, Shen Z. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway. Tumour Biol. 35, 9139-46 (2014)
PubMed link      E-mail link

Reference Number: 1654
Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res. 20, 4559-73 (2014)
PubMed link      E-mail link

Reference Number: 1680
Zhang L, Xia L, Zhao L, Chen Z, Shang X, Xin J, Liu M, Guo X, Wu K, Pan Y, Fan D. Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. Carcinogenesis. 36, 390-9 (2015)
PubMed link      E-mail link

Reference Number: 1714
Sun L, Duan J, Jiang Y, Wang L, Huang N, Lin L, Liao Y, Liao W Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer. Cancer Lett. 357, 242-53 (2015)
PubMed link      E-mail link

Reference Number: 1718
Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 136, 1629-35 (2015)
PubMed link      E-mail link

Reference Number: 1727
Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, Shaker MN, Hamakawa T, Takahashi T, Takiguchi S, Mori M, Doki Y. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 21 Suppl 4, S584-90 (2014)
PubMed link      E-mail link

Reference Number: 1740
Choi J, Lee HE, Kim MA, Jang BG, Lee HS, Kim WH. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization. PLoS One. 9, e111658 (2014)
PubMed link      E-mail link

Reference Number: 1741
Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget. 6, 221-33 (2015)
PubMed link      E-mail link

Reference Number: 1784
Ma JA, Hu C, Li W, Ren J, Zou F, Zhou D, Zou W, Wei Y, Zhou Y. Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib. Mol Med Rep. 11, 2269-75 (2015)
PubMed link      E-mail link

Reference Number: 1785
Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Höfler H, Luber B. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J Cancer Res Clin Oncol. 138, 843-58 (2012)
PubMed link      E-mail link

Reference Number: 1810
Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, Ma J, Cai D, Gu X. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 34, 35 (2015)
PubMed link      E-mail link

Reference Number: 1811
Zhu C, Xu J, Li M, Zhao G, Cao H. Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol. 46, 1901-7 (2015)
PubMed link      E-mail link

Reference Number: 1813
Noguchi E, Saito N, Kobayashi M, Kameoka S. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 11, 3423-31 (2015)
PubMed link      E-mail link

Reference Number: 1839
Zheng Z, Yan D, Chen X, Huang H, Chen K, Li G, Zhou L, Zheng D, Tu L, Dong XD. MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway. PLoS One. 10, e0128751 (2015)
PubMed link      E-mail link

Reference Number: 1853
Wu Z, Wang H, Fang S, Xu C. MiR-449c inhibits gastric carcinoma growth. Life Sci. 137, 14-9 (2015)
PubMed link      E-mail link

Reference Number: 1876
Kim ST, Do IG, Lee J, Sohn I, Kim KM, Kang WK. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. Clin Transl Oncol. 17, 462-8 (2015)
PubMed link      E-mail link

Reference Number: 1881
Koch C, Trojan J. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. Digestion. 91, 294-302 (2015)
PubMed link      E-mail link